瑞巴派特改良四联疗法在幽门螺杆菌阳性胃溃疡治疗中的临床效果及安全性分析  

Clinical Effect and Safety Analysis of Rebamipide Modified Quadruple Chemotherapy in the Treatment of Helicobacter Pylori Positive Gastric Ulcer

作　　者：刘镜军 王雪霞 王永升 LIU Jingjun;WANG Xuexia;WANG Yongsheng(Department of Pharmacy,Shanxian Central Hospital,Heze,Shandong,274000,China)

机构地区：[1]单县中心医院药剂科,山东菏泽274000

出　　处：《中外医疗》2024年第33期80-83,88,共5页China & Foreign Medical Treatment

摘　　要：目的 探究瑞巴派特改良四联疗法在治疗幽门螺杆菌(helicobacter pylori,Hp)阳性胃溃疡中的临床疗效及安全性。方法 方便选取2023年1月—2024年4月单县中心医院收治的146例Hp阳性胃溃疡患者为研究对象,根据不同治疗方法分为常规组和探究组。常规组(73例)接受含铋剂四联疗法治疗,探究组(73例)应用瑞巴派特改良四联疗法治疗。对比两组炎性因子水平、胃黏膜形态学水平、胃功能、不良反应总发生率和Hp根除率。结果 治疗后,探究组炎性因子水平低于常规组,差异有统计学意义(P<0.05)。探究组胃黏膜形态学水平和胃功能均优于常规组,差异均有统计学意义(P均<0.05)。探究组不良反应发生率为6.85%(5/73),低于常规组的17.81%(13/73),探究组Hp根除率为94.52%(69/73),高于常规组的82.19%(60/73),差异有统计学意义(χ^(2)=4.056,5.393;P均<0.05)。结论 在Hp阳性胃溃疡的治疗中,相较于传统的含铋剂四联疗法,瑞巴派特改良四联疗法能改善炎性反应、胃功能及胃黏膜病变严重程度,且不良反应发生率低,Hp根除率高。Objective To explore the clinical efficacy and safety of rebamipide modified quadruple chemotherapy in the treatment of helicobacter pylori(Hp) positive gastric ulcer.Methods A total of 146 patients with Hp-positive gastric ulcer admitted to Shanxian Central Hospital from January 2023 to April 2024 were selected as the research objects.According to different treatment methods,they were divided into conventional group and exploration group.The conventional group(73 cases) received bismuth-containing quadruple chematherapy,and the exploration group(73cases) was treated with rebamipide modified quadruple chemotherapy.The levels of inflammatory factors,gastric mucosal morphology,gastric function,the total incidence of adverse reactions and Hp eradication rate were compared between the two groups.Results After treatment,the level of inflammatory factors in the exploration group was lower than that in the conventional group,and the difference was statistically significant(P<0.05).The morphological level of gastric mucosa and gastric function in the exploration group were better than those in the conventional group,and the differences were statistically significant(both P<0.05).The incidence of adverse reactions in the exploration group was 6.85%(5/73),which was lower than 17.81%(13/73) in the conventional group,and the eradication rate of Hp in the exploration group was 94.52%(69/73),which was higher than 82.19%(60/73) in the conventional group,the differences were statistically significant(χ^(2)=4.056,5.393;both P<0.05).Conclusion In the treatment of Hp-positive gastric ulcer,compared with traditional bismuth-containing quadruple chemotherapy,rebamipide modified quadruple chematherapy can improve inflammatory response,gastric function and severity of gastric mucosal lesions,with low incidence of adverse reactions and high eradication rate of Hp.

关 键 词：瑞巴派特 四联疗法 幽门螺杆菌 临床效果 安全性 

分 类 号：R573.1[医药卫生—消化系统]